These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 25632141)

  • 41. Viral Delivery of Non-Mutated Human Truncated Tau to Neurons Recapitulates Key Features of Human Tauopathy in Wild-Type Mice.
    Vogels T; Vargová G; Brezováková V; Quint WH; Hromádka T
    J Alzheimers Dis; 2020; 77(2):551-568. PubMed ID: 32675411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The catalytic subunit of telomerase is expressed in developing brain neurons and serves a cell survival-promoting function.
    Fu W; Killen M; Culmsee C; Dhar S; Pandita TK; Mattson MP
    J Mol Neurosci; 2000; 14(1-2):3-15. PubMed ID: 10854032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies.
    Vingtdeux V; Davies P; Dickson DW; Marambaud P
    Acta Neuropathol; 2011 Mar; 121(3):337-49. PubMed ID: 20957377
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART.
    Kaufman SK; Del Tredici K; Thomas TL; Braak H; Diamond MI
    Acta Neuropathol; 2018 Jul; 136(1):57-67. PubMed ID: 29752551
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The use of mouse models to study cell-to-cell transmission of pathological tau.
    Narasimhan S; Lee VMY
    Methods Cell Biol; 2017; 141():287-305. PubMed ID: 28882308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
    Ferrer I; Gomez-Isla T; Puig B; Freixes M; Ribé E; Dalfó E; Avila J
    Curr Alzheimer Res; 2005 Jan; 2(1):3-18. PubMed ID: 15977985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disruption of endoplasmic reticulum-mitochondria tethering proteins in post-mortem Alzheimer's disease brain.
    Lau DHW; Paillusson S; Hartopp N; Rupawala H; Mórotz GM; Gomez-Suaga P; Greig J; Troakes C; Noble W; Miller CCJ
    Neurobiol Dis; 2020 Sep; 143():105020. PubMed ID: 32682953
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic ablation of tau in postnatal neurons rescues decreased adult hippocampal neurogenesis in a tauopathy model.
    Houben S; Leroy K; Ando K; Yilmaz Z; Widomski C; Buée L; Brion JP
    Neurobiol Dis; 2019 Jul; 127():131-141. PubMed ID: 30818066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Microglial immunophenotype in dementia with Alzheimer's pathology.
    Minett T; Classey J; Matthews FE; Fahrenhold M; Taga M; Brayne C; Ince PG; Nicoll JA; Boche D;
    J Neuroinflammation; 2016 Jun; 13(1):135. PubMed ID: 27256292
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer's disease and Creutzfeldt-Jakob's disease.
    Ferrer I
    Neuropathol Appl Neurobiol; 2002 Dec; 28(6):441-51. PubMed ID: 12445160
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy.
    Cente M; Filipcik P; Pevalova M; Novak M
    Eur J Neurosci; 2006 Aug; 24(4):1085-90. PubMed ID: 16930434
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Telomere shortening reduces Alzheimer's disease amyloid pathology in mice.
    Rolyan H; Scheffold A; Heinrich A; Begus-Nahrmann Y; Langkopf BH; Hölter SM; Vogt-Weisenhorn DM; Liss B; Wurst W; Lie DC; Thal DR; Biber K; Rudolph KL
    Brain; 2011 Jul; 134(Pt 7):2044-56. PubMed ID: 21672962
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model.
    Zhang ZH; Wu QY; Zheng R; Chen C; Chen Y; Liu Q; Hoffmann PR; Ni JZ; Song GL
    J Neurosci; 2017 Mar; 37(9):2449-2462. PubMed ID: 28137967
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neurons derived from sporadic Alzheimer's disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation.
    Ochalek A; Mihalik B; Avci HX; Chandrasekaran A; Téglási A; Bock I; Giudice ML; Táncos Z; Molnár K; László L; Nielsen JE; Holst B; Freude K; Hyttel P; Kobolák J; Dinnyés A
    Alzheimers Res Ther; 2017 Dec; 9(1):90. PubMed ID: 29191219
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tau pathology is present in vivo and develops in vitro in sensory neurons from human P301S tau transgenic mice: a system for screening drugs against tauopathies.
    Mellone M; Kestoras D; Andrews MR; Dassie E; Crowther RA; Stokin GB; Tinsley J; Horne G; Goedert M; Tolkovsky AM; Spillantini MG
    J Neurosci; 2013 Nov; 33(46):18175-89. PubMed ID: 24227726
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Propagation of tau pathology in a model of early Alzheimer's disease.
    de Calignon A; Polydoro M; Suárez-Calvet M; William C; Adamowicz DH; Kopeikina KJ; Pitstick R; Sahara N; Ashe KH; Carlson GA; Spires-Jones TL; Hyman BT
    Neuron; 2012 Feb; 73(4):685-97. PubMed ID: 22365544
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections.
    Iba M; McBride JD; Guo JL; Zhang B; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2015 Sep; 130(3):349-62. PubMed ID: 26150341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy.
    Gourmaud S; Shou H; Irwin DJ; Sansalone K; Jacobs LM; Lucas TH; Marsh ED; Davis KA; Jensen FE; Talos DM
    Brain; 2020 Jan; 143(1):191-209. PubMed ID: 31834353
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy.
    Blair LJ; Frauen HD; Zhang B; Nordhues BA; Bijan S; Lin YC; Zamudio F; Hernandez LD; Sabbagh JJ; Selenica ML; Dickey CA
    Acta Neuropathol Commun; 2015 Jan; 3():8. PubMed ID: 25775028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.